Therapeutic potential of oncolytic measles virus: Promises and challenges

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 5, 2010, Pages 620-625

  Galanis, E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; MEASLES VACCINE; ONCOLYTIC VIRUS;

ANTINEOPLASTIC ACTIVITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DOSE RESPONSE; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG SAFETY; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MEASLES VIRUS; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RECURRENT CANCER; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PATHOGENICITY; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MEASLES VIRUS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TREATMENT OUTCOME;

EID: 77958501444     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.211     Document Type: Review

References (52)

1. Bluming, A.Z. & Ziegler, J.L. Regression of Burkitt's lymphoma in association with measles infection. Lancet 2, 105-106 (1971).
2. Pasquinucci, G. Possible efect of measles on leukaemia. Lancet 1, 136 (1971).
3. Taqi, A.M., Abdurrahman, M.B., Yakubu, A.M. & Fleming, A.F. Regression of Hodgkin's disease after measles. Lancet 1, 1112 (1981).
4. Cutts, F.T. & Markowitz, L.E. Successes and failures in measles control. J. Infect. Dis. 170 (suppl. 1), S32-S41 (1994).
5. Tatsuo, H., Ono, N., Tanaka, K. & Yanagi, Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406, 893-897 (2000).
6. Naniche, D. et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67, 6025-6032 (1993).
7. Dörig, R.E., Marcil, A., Chopra, A. & Richardson, C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75, 295-305 (1993).
8. Yanagi, Y [The cellular receptor for measles virus]. Uirusu. 51, 201-208 (2001).
9. Fishelson, Z., Donin, N., Zell, S., Schultz, S. & Kirschfnk, M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40, 109-123 (2003).
10. Anderson, B.D., Nakamura, T., Russell, S.J. & Peng, K.W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 64, 4919-4926 (2004).
11. Wild, T.F., Malvoisin, E. & Buckland, R. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J. Gen. Virol. 72 (Pt 2), 439-442 (1991).
12. Galanis, E. et al. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum. Gene Ther. 12, 811-821 (2001).
13. Peng, K.W. et al. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther. 13, 732-738 (2006).
14. Dingli, D. et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103, 1641-1646 (2004).
15. Phuong, L.K. et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 63, 2462-2469 (2003).
16. Studebaker, A.W., Kreofsky, C.R., Pierson, C.R., Russell, S.J., Galanis, E. & Rafel, C. Treatment of medulloblastoma with a modifed measles virus. Neuro. Oncol. (2010); e-pub ahead of print 21 May 2010.
17. Msaouel, P. et al. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 69, 82-91 (2009).
18. Msaouel, P. et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol. Ther. 17, 2041-2048 (2009).
19. Blechacz, B. et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 44, 1465-1477 (2006).
20. McDonald, C.J. et al. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res. Treat. 99, 177-184 (2006).
21. Iankov, I.D. et al. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural efusion breast cancer model. Breast Cancer Res. Treat. 122, 745-754 (2010).
22. Grote, D. et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodefcient mice. Blood 97, 3746-3754 (2001).
23. Radecke, F. et al. Rescue of measles viruses from cloned DNA. EMBO J. 14, 5773-5784 (1995).
24. Ungerechts, G. et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fudarabine. Cancer Res. 67, 10939-10947 (2007).
25. Nakamura, T. et al. Antibody-targeted cell fusion. Nat. Biotechnol. 22, 331-336 (2004).
26. Vongpunsawad, S., Oezgun, N., Braun, W. & Cattaneo, R. Selectively receptor-blind measles viruses: identifcation of residues necessary for SLAM-or CD46-induced fusion and their localization on a new hemagglutinin structural model. J. Virol. 78, 302-313 (2004).
27. Nakamura, T. et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 23, 209-214 (2005).
28. Paraskevakou, G. et al. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains efectively target EGFR-or EGFRvIII expressing gliomas. Mol. Ther. 15, 677-686 (2007).
29. Allen, C. et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain signifcant antitumor activity against gliomas with increased tumor specifcity. Cancer Res. 66, 11840-11850 (2006).
30. Hasegawa, K. et al. The use of a tropism-modifed measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin. Cancer Res. 12, 6170-6178 (2006).
31. Hasegawa, K., Hu, C., Nakamura, T., Marks, J.D., Russell, S.J. & Peng, K.W. Afnity thresholds for membrane fusion triggering by viral glycoproteins. J. Virol. 81, 13149-13157 (2007).
32. Allen, C. et al. Interleukin-13 displaying retargeted oncolytic measles virus strains have signifcant activity against gliomas with improved specifcity. Mol. Ther. 16, 1556-1564 (2008).
33. Springfeld, C., von Messling, V., Frenzke, M., Ungerechts, G., Buchholz, C.J. & Cattaneo, R. Oncolytic efcacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res. 66, 7694-7700 (2006).
34. Allen, C. et al. IL13 displaying retargeted oncolytic measles virus (MV) strains have signifcant activity and improved therapeutic index against gliomas. Mol Ther 15 (suppl. 1), s22 (2007).
35. Mrkic, B. et al. Measles virus spread and pathogenesis in genetically modifed mice. J. Virol. 72, 7420-7427 (1998).
36. Myers, R. et al. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum. Gene Ther. 19, 690-698 (2008).
37. Myers, R.M. et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin. Pharmacol. Ther. 82, 700-710 (2007).
38. Allen, C. et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin. Biol. Ther. 8, 213-220 (2008).
39. Peng, K.W. et al. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum. Gene Ther. 14, 1565-1577 (2003).
40. Msaouel, P. , Dispenzieri, A. & Galanis, E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr. Opin. Mol. Ther. 11, 43-53 (2009).
41. Galanis, E. et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 70, 875-882 (2010).
42. NCT00390299: Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme (2008).
43. NCT00450814: Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma (2008).
44. Markman, M., Webster, K., Zanotti, K., Peterson, G., Kulp, B. & Belinson, J. Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol. Oncol. 93, 699-701 (2004).
45. Fulci, G. et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. USA 103, 12873-12878 (2006). (Pubitemid 44298654)
46. Fulci, G. et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res. 67, 9398-9406 (2007).
47. Ikeda, K. et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5, 881-887 (1999).
48. Tyminski, E. et al. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res. 65, 6850-6857 (2005).
49. Mader, E.K. et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin. Cancer Res. 15, 7246-7255 (2009).
50. Iankov, I.D. et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol. Ther. 15, 114-122 (2007).
51. Liu, C. et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin. Cancer Res. 13, 7155-7165 (2007).
52. Liu, C. et al. Heat shock protein inhibitors increase the efcacy of measles virotherapy. Gene Ther. 15, 1024-1034 (2008).